We are live on ! Find out more
TRIL

Trillium Therapeutics Inc.
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

29 hedge funds and large institutions have $48.9M invested in Trillium Therapeutics Inc. in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

9% more capital invested

Capital invested by funds: $44.8M → $48.9M (+$4.11M)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

12% less funds holding

Funds holding: 3329 (-4)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Holders
29
Holders Change
-4
Holders Change %
-12.12%
% of All Funds
0.76%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
4
Increased
8
Reduced
8
Closed
8
Calls
Puts
Net Calls
Net Calls Change

TRIL Hedge Fund Activity: Q4 2015 in Review

29 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2015, worth a combined $48.9M — up 9.2% from $44.8M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of TRIL and 4 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.

The largest buyer was Baker Bros. Advisors, adding an estimated $2.07M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.22M sold.

  • 29 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2015, down from 33 in Q3 2015.
  • Funds reported $48.9M of Trillium Therapeutics Inc. stock for Q4 2015, up 9.2% quarter-over-quarter.
  • 4 funds opened new Trillium Therapeutics Inc. positions in Q4 2015 and 8 closed out, a net change of -4 holders.
  • The largest Trillium Therapeutics Inc. buyer in Q4 2015 was Baker Bros. Advisors, an estimated $2.07M added.
  • The largest Trillium Therapeutics Inc. seller in Q4 2015 was Fidelity Investments, an estimated $1.22M sold.

Based on aggregated 13F filings for Q4 2015.